Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 15;57(2):73-81.
doi: 10.2176/nmc.ra.2016-0056. Epub 2016 May 11.

Multimodal Treatment Strategy for Spetzler-Martin Grade III Arteriovenous Malformations of the Brain

Affiliations
Review

Multimodal Treatment Strategy for Spetzler-Martin Grade III Arteriovenous Malformations of the Brain

Bikei Ryu et al. Neurol Med Chir (Tokyo). .

Abstract

The Spetzler-Martin (S-M) grading scale was developed to assess the risk of postoperative neurological complications after the surgical treatment of arteriovenous malformations (AVMs) of the brain. Treatment-associated morbidity and poor outcomes are particularly relevant to Grade III AVMs and improving the safety while attaining acceptable cure rates still poses a challenge. A multimodal treatment strategy combining surgery, embolization, and radiosurgery is recommended for S-M Grade III AVMs because of the surgical risk. Grade III AVMs are the heterogeneous group that has been further divided into subgroups according to the size, the location in eloquent cortex, and the presence of deep venous drainage. The risks associated with different treatment modalities vary depending on the subgroup, and the rating scales have been further refined to predict the risk more accurately and help determine the most appropriate treatment choice. Previous results for the treatment of S-M Grade III AVMs vary widely among studies, and the treatment modalities are also different in each study. Being familiar with previous treatment results is essential for improving treatment outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Disclosure

The authors have no disclosures to report.

References

    1. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ: Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 383: 614– 621, 2014. - PMC - PubMed
    1. Al-Shahi Salman R, White PM, Counsell CE, du Plessis J, van Beijnum J, Josephson CB, Wilkinson T, Wedderburn CJ, Chandy Z, St George EJ, Sellar RJ, Warlow CP: Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. JAMA 311: 1661– 1669, 2014. - PubMed
    1. Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. J Neurosurg 65: 476– 483, 1986. - PubMed
    1. Spetzler RF, Ponce FA: A 3-tier classification of cerebral arteriovenous malformations. Clinical article. J Neurosurg 114: 842– 849, 2011. - PubMed
    1. Ogilvy CS, Stieg PE, Awad I, Brown RD, Jr, Kondziolka D, Rosenwasser R, Young WL, Hademenos G: AHA Scientific statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke 32: 1458– 1471, 2001. - PubMed

MeSH terms